A Phase 1-2, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma.

Trial Profile

A Phase 1-2, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs Namodenoson (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 28 Aug 2013 Data from this study were published in The Oncologist in January 2013, and will be presented at the 18th World Congress on Advances in Oncology, according to a Can-Fite BioPharma media release.
    • 01 Mar 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 03 Jan 2012 Results published in a Can-Fite BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top